Cargando…
Therapeutic Potential of Senolytics in Cardiovascular Disease
Ageing is the biggest risk factor for impaired cardiovascular health, with cardiovascular disease being the leading cause of death in 40% of individuals over 65 years old. Ageing is associated with both an increased prevalence of cardiovascular disease including heart failure, coronary artery diseas...
Autores principales: | Dookun, Emily, Passos, João F., Arthur, Helen M., Richardson, Gavin D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770386/ https://www.ncbi.nlm.nih.gov/pubmed/32979174 http://dx.doi.org/10.1007/s10557-020-07075-w |
Ejemplares similares
-
Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls
por: Owens, W Andrew, et al.
Publicado: (2021) -
Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson’s Disease
por: Miller, Sean J., et al.
Publicado: (2022) -
Strategies for senolytic drug discovery
por: Power, Helen, et al.
Publicado: (2023) -
Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction
por: Walaszczyk, Anna, et al.
Publicado: (2019) -
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)